Skip to main content

Table 1 Body weight and fasting blood glucose in WKY, WKY + SAL, GK, and GK + SAL rats in Experiment I, Experiment II, and Experiment III

From: Salidroside contributes to reducing blood pressure and alleviating cerebrovascular contractile activity in diabetic Goto-Kakizaki Rats by inhibition of L-type calcium channel in smooth muscle cells

  20-week of age 24-week of age
(4 weeks SAL treatment)
Body weight (g) Blood glucose (mM) Body weight (g) Blood glucose (mM)
Experiment I
 WKY(n = 10) 375.0 ± 11.5 5.2 ± 1.7 418.0 ± 18.8 5.2 ± 1.3
 WKY + 50 mg/kg/day SAL(n = 10) 383.8 ± 10.2 5.4 ± 1.3 409.5 ± 15.5 4.9 ± 1.8
 GK(n = 10) 389.0 ± 11.6 9.2 ± 2.4* 427.0 ± 12.3 11.6 ± 1.9*
 GK + 50 mg/kg/day SAL(n = 10) 391.0 ± 11.4 8.6 ± 2.1* 419.0 ± 18.9 10.2 ± 1.3*
Experiment II
 WKY(n = 15) 386.0 ± 15 5.26 ± 1.2 412.5 ± 17.8 5.8 ± 0.9
 WKY + 100 mg/kg/day SAL(n = 15) 378.5 ± 13 5.4 ± 2.2 426.9 ± 15.3 5.7 ± 1.2
 GK(n = 15) 392.0 ± 18 8.9 ± 1.3* 431.3 ± 16.3 10.5 ± 1.4*
 GK + 100 mg/kg/day SAL(n = 15) 387.0 ± 17 9.1 ± 1.6* 425.0 ± 11.2 7.8 ± 1.5#*
Experiment III
 WKY(n = 10) 378.0 ± 11.0 4.7 ± 1.5 408.0 ± 17.2 5.8 ± 1.6
 WKY + 200 mg/kg/day SAL(n = 10) 383.2 ± 13.6 5.2 ± 1.1 415.5 ± 16.5 3.4 ± 1.8*
 GK(n = 10) 389.0 ± 12.7 8.5 ± 1.2* 436.0 ± 12.7 11.2 ± 1.5*
 GK + 200 mg/kg/day SAL(n = 10) 393.0 ± 16.5 8.9 ± 1.0* 428.0 ± 15.2 8.1 ± 3.3#*
  1. WKY Control WKY rats, WKY + SAL WKY rats administrated with SAL, GK Diabetic GK rats, GK + SAL GK rats administrated with SAL. SAL was administrated with different dosage of 50, 100 and 200 mg/kg/day for 4 weeks in Experiment I, Experiment II, and Experiment III, respectively. *P < 0.05 vs. WKY and # P < 0.05 vs. GK rats
\